Myovant Sciences Ltd. (NYSE:MYOV) went down by -7.06% from its latest closing price compared to the recent 1-year high of $30.90. The company’s stock price has collected -14.80% of loss in the last five trading sessions. Press Release reported on 09/09/21 that Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE(R) for the Management of Moderate to Severe Pain Associated With Endometriosis
Is It Worth Investing in Myovant Sciences Ltd. (NYSE :MYOV) Right Now?
Plus, the 36-month beta value for MYOV is at 2.84. Opinions of the stock are interesting as 3 analysts out of 6 who provided ratings for Myovant Sciences Ltd. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 2 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $31.40, which is $12.21 above the current price. MYOV currently public float of 33.16M and currently shorts hold a 13.11% ratio of that float. Today, the average trading volume of MYOV was 707.52K shares.
MYOV’s Market Performance
MYOV stocks went down by -14.80% for the week, with a monthly jump of 3.26% and a quarterly performance of 4.64%, while its annual performance rate touched 13.33%. The volatility ratio for the week stands at 5.37% while the volatility levels for the past 30 days are set at 4.80% for Myovant Sciences Ltd.. The simple moving average for the period of the last 20 days is -2.71% for MYOV stocks with a simple moving average of 2.71% for the last 200 days.
Analysts’ Opinion of MYOV
Many brokerage firms have already submitted their reports for MYOV stocks, with SVB Leerink repeating the rating for MYOV by listing it as a “Mkt Perform.” The predicted price for MYOV in the upcoming period, according to SVB Leerink is $24 based on the research report published on September 09th of the current year 2021.
Goldman, on the other hand, stated in their research note that they expect to see MYOV reach a price target of $18. The rating they have provided for MYOV stocks is “Neutral” according to the report published on August 20th, 2021.
SVB Leerink gave a rating of “Mkt Perform” to MYOV, setting the target price at $28 in the report published on January 08th of the current year.
MYOV Trading at 4.57% from the 50-Day Moving Average
After a stumble in the market that brought MYOV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -26.25% of loss for the given period.
Volatility was left at 4.80%, however, over the last 30 days, the volatility rate increased by 5.37%, as shares surge +5.90% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.04% upper at present.
During the last 5 trading sessions, MYOV fell by -14.80%, which changed the moving average for the period of 200-days by +6.20% in comparison to the 20-day moving average, which settled at $23.49. In addition, Myovant Sciences Ltd. saw -17.49% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at MYOV starting from Sumitomo Chemical Co., Ltd., who purchase 37,000 shares at the price of $25.52 back on Sep 09. After this action, Sumitomo Chemical Co., Ltd. now owns 49,354,180 shares of Myovant Sciences Ltd., valued at $944,147 using the latest closing price.
Curran Terrie, the Director of Myovant Sciences Ltd., sale 4,850 shares at $25.58 during a trade that took place back on Sep 09, which means that Curran Terrie is holding 0 shares at $124,063 based on the most recent closing price.
Stock Fundamentals for MYOV
Current profitability levels for the company are sitting at:
- -439.64 for the present operating margin
- +92.51 for the gross margin
The net margin for Myovant Sciences Ltd. stands at -430.12. The total capital return value is set at -1,549.24, while invested capital returns managed to touch -1,681.67. Equity return is now at value 92.80, with -48.10 for asset returns.
When we switch over and look at the enterprise to sales, we see a ratio of 25.92, with the company’s debt to enterprise value settled at 0.24. The receivables turnover for the company is 33.23 and the total asset turnover is 0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.50.